tbuckley/cabot-search huggingface dataset:
Association of gene signature to identify molecular subtypes with clinical outcomes of 1st-line cetuximab (cet) treatment for metastatic colorectal cancer (mCRC).
Authors: Yu Sunakawa, Eva Wang, Chris Roberts, Dongyun Yang, Qian Liu, Debrah Thompson, Ihab Botros, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Wu Zhang, Sebastian Stintzing, Akihito Tsuji, Takehiro Takahashi, Tadamichi Denda, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima, Wataru Ichikawa, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2016)

3592 Background: Recently, several groups have reported on classifications of CRC using gene expression data to identify distinct subtypes (Guinney J, et al. Nat med 2015). Some studies found one subtype which has poor prognosis and does not respond to cet (Sadanandam A, et al. Nat Med 2013; De Sousa E Melo F, et al. Nat Med 2013). However, few subtyping studies focused on efficacy of cet as an initial therapy for mCRC. We therefore investigated whether the gene signature will predict outcomes in mCRC patients (pts) received 1st-line cet treatment. Methods: We analyzed total RNA isolated from tissue samples of 77 KRAS wild-type pts enrolled in 2 phase II trials (JACCRO CC-05:UMIN000004197 or CC-06:UMIN000007022) evaluating cet plus oxaliplatin-based chemotherapy as 1st-line treatment. Gene expression levels were measured by HTG EdgeSeq Oncology Biomarker Panel, which is comprised of probes targeting 2560 genes implicated in numbers of pathways, using next generation sequencing for quantitative analysis of targeted RNAs. Univariate Cox regression analysis was conducted for all genes that passed QC filtering. Hierarchical clustering was performed using genes under 0.005 of the Cox p-value. Results: The patient cohort comprised 57% males, median age of 63 years, 90% of performance status 0 and 15% of right colon cancer. The Cox regression analysis identified 24 genes to be with less than 0.005 of p-value for overall survival (OS). CDX2, which recently identified to be a novel prognostic marker in colon cancer (N Engl J Med 2016), ranked as first gene associated with OS as well as progression-free survival (PFS) (p= 5.56×10-5, FDR.p= 0.058 and p= 5.09×10-5, FDR.p= 0.053, respectively). The hierarchical clustering using the 24 genes could classify all participants into 3 groups and the Kaplan-Meier curve of the groups had a significant difference in OS (mean 13.6 vs. 19.8 vs. 28.1 months, p= 2.84e-06) but not in PFS. Conclusions: Multigene-expression signature may predict outcomes of 1st-line cet treatment in mCRC pts. These preliminary data warrants further confirmation clinical trials: validation of our findings in FIRE3 trial is ongoing.
Omega-3 Carboxylic Acids, Epanova®, and the Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin®, Improve Steatohepatitis and Fibrosis Scoring in a Mouse Model of Non-Alcoholic Steatohepatitis
Authors: S. Cazanave, B. Banini, A. Asgharpour, R. Vincent, M. Seneshaw, D. Prassana Kumar, F. Mirshahi, K. Daita, P. Puri, J. Oscarsson, P. Bedossa, A. Sanyal
Journal: Journal of Hepatology (2016)
Supplemental Feedings for High-Risk Preterm Infants
Authors: Sergio Verd
Journal: JAMA Pediatrics (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Novel endothelial-protective effect of high density lipoprotein: Down-regulation of toll-like receptor 4
Authors: Frank Spillmann, Sophie Van Linthout, Aysun Subasigueller, Carola Buecker-Gaertner, Meloni Meloni, Marina Egorova, Bart De Geest, Heinz-Peter Schultheiss, Carsten Tschoepe
Journal: Circulation (2007)
Survival from head and neck cancers based on socioeconomic status in Asians.
Authors: K. P. Chu, S. J. Shema, S. Wu, S. L. Gomez, E. T. Chang, Q. Le
Journal: Journal of Clinical Oncology (2010)

5596 Background: Lower socioeconomic status (SES) has been linked with higher incidence and lower survival in head and neck cancer (HNC) patients. However, there is little data on outcomes in Asians/Pacific Islanders (APIs) with HNC. The purposes of this study are to examine the effect of SES on overall survival (OS) in APIs with HNC and to compare their survival to that of other ethnicities using population-based registry data. Methods: 53,544 eligible HNC patients (of whom 4,711 were APIs) were identified from the California Cancer Registry from 1988 to 2007. Block-group SES, based on a composite of Census 1990 and 2000 data, was calculated for each patient based on address at diagnosis. SES was categorized into 2 groups for comparison (low SES = quintiles 1-3; high SES = quintiles 4-5). For each HNC site, descriptive data, treatment, and outcomes were recorded. OS was computed by the Kaplan- Meier method. Adjusted hazard ratios (HR) were estimated using Cox proportional hazards regression models. Results: In all patients combined, lower SES was significantly associated with poorer OS for all HNC sites. APIs had significantly better OS compared to Caucasians for OC, adjusted hazard ratio (HR) 0.83 (95% CI 0.76–0.90); LX/HP, HR 0.74 (95% CI 0.68–0.81); and NP, HR 0.82 (95% CI 0.74–0.90). OS benefit was preserved in both lower SES and higher SES strata (Table). After adjustment for other parameters, lower SES was significantly associated with poorer survival among APIs with OC, OPC, and LX/HP analyzed together. Conclusions: Neighborhood SES significantly influences survival in APIs with HNC, consistent with previous studies of other racial/ethnic groups. Unexpectedly, the higher median OS for APIs compared to Caucasians persisted for most HNC sites across levels of SES. This racial difference in HNC survival requires further elucidation for future individualized care. Median survival (months) by tumor site and SES for all, Caucasians, and API patients with HNC Tumor site All patients Caucasians API High SES Low SES High SES Low SES High SES Low SES Oral cavity (OC) 62.4 38.1 61.7 40.9 91.0 40.9 Oropharynx (OP) 85.4 36.7 86.2 43.7 101.7 38.8 Larynx/ hypopharynx (LX/HP) 74.6 49.3 73.9 50.8 119.1 59.3 Nasopharynx (NP) 100.9 61.3 64.1 35.4 148.4 83.1 No significant financial relationships to disclose.
CD24High / FLJ/P1Low Expression Correlates with Bad Prognosis and Shorter Survival in Adult ALL.
Authors: Lionel J. Coignet, Thimothy Johnson, Alain Nganga, Qing Zhang, Corinna Meyer, Hans G. Drexler, Debashis Ghosh, Keshav Singh, Maria R. Baer
Journal: Blood (2005)
Alfapump® System versus Large Volume Paracentesis in the Treatment of Refractory Ascites; Results from a Multicenter Randomised Controlled Study (Rct)
Authors: D. Adebayo, C. Bureau, M.C. de Rieu, D. Valla, L. Elkrief, M. Peck-Radosavljevic, S. Bota, A. McCune, R. Abbadi, V. Vargas, M. Simon-Talero, J. Cordoba, P. Angeli, S. Rosi, S. Macdonald, S. Whittaker, C. Trepte, R. Jalan
Journal: Journal of Hepatology (2016)
The Challenge of Using CB-HSCs As Source for Gene Therapy: Lentiviral Vector Transduction, Phenotypic Characterization and Global Gene Expression Profile of Ex-Vivo Expanded CB CD34+ Cells
Authors: Rosalia Di Stefano, Elena Baiamonte, Melania Lo Iacono, Barbara Spina, Flavia Contino, Claudia Coronnello, Massimiliano Sacco, Rosario Di Maggio, Angela Vitrano, Salvatore Feo, Aurelio Maggio, Santina Acuto
Journal: Blood (2015)
Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models
Authors: Robert U Svensson, Seth J Parker, Lillian J Eichner, Matthew J Kolar, Martina Wallace, Sonja N Brun, Portia S Lombardo, Jeanine L Van Nostrand, Amanda Hutchins, Lilliana Vera, Laurie Gerken, Jeremy Greenwood, Sathesh Bhat, Geraldine Harriman, William F Westlin, H James Harwood, Alan Saghatelian, Rosana Kapeller, Christian M Metallo, Reuben J Shaw
Journal: Nature Medicine (2016)
Pre-Treatment Reduction in Sensitivity to Sofosbuvir and Ribavirin in Patients with Genotype 3 Hepatitis C Virus who Relapse following all Oral Antiviral Therapy
Authors: P. Wing, A. Filipe, M.E. Cunningham, S. De Silva, M. Cheung, M. Jones, W. Irving, J. McLauchlan, G.R. Foster
Journal: Journal of Hepatology (2016)
Identifying variables influencing the efficiency and efficacy of a multidisciplinary team meeting.
Authors: Yara L. Basta, Onno L. Baur, Susan van Dieren, Jean H. G. Klinkenbijl, Kristien M. A. J. Tytgat
Journal: Journal of Clinical Oncology (2015)

730 Background: Multidisciplinary team meetings (MDM) provide a platform for discussing diagnoses and treatments. Since many healthcare settings have accepted multidisciplinary care as best practice, avenues towards improving MDMs should be investigated. This study aimed to identify variables that influence the efficiency and efficacy of an MDM in a tertiary referral center in the Netherlands. Methods: Consecutive MDMs for hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), esophageal and gastric cancer (ESOGAS) and pancreatobiliary and liver cancer (HPB) were studied. Efficiency was measured as duration of the MDM. Efficacy was assessed by accurate diagnoses. Logistic and linear regression models identified variables influencing the efficiency and efficacy. Results: In 74 MDMs with a mean duration of 63 min (SD 14), 700 patients were discussed of which 114 patients at ≥2 MDMs. A median of 10 patients was discussed per MDM (IQR 6 – 14). Mean discussion time per patient was 05:19 min (SD 2). Corrected for tumor type, the number of patients discussed and the presence of others (e.g., research fellows) in addition to medical specialists, prolonged the MDM (+1.9 min CI 1.2 – 2.6; +0.64 min; CI 0.23 – 1.5 resp.). Including a follow up patient in the MDM, decreased the duration by 3.9 min (CI -5.8 – -2.0). The diagnostic accuracy of the MDM was 95%. The duration of the MDM or number of patients discussed did not influence this (OR 1.1 CI 0.99 – 1.0; OR 0.92 CI 0.79 – 1.1 resp.). The diagnosis was accurately altered for 117 (21%) patients, for 1 patient it was altered incorrectly. Tumor type predicted the accurate diagnoses (OR 0.1 CI 0.02 – 0.71; OR 2.0 CI 0.46 – 8.6; OR 3.1 CI 1.3 – 7.4; for HCC, CRC and ESOGAS respectively. Reference group: HPB). A correct diagnosis was more likely if patients’ cases were presented by their own doctor (OR 5.0 CI 2.0 – 12.5). Conclusions: MDMs play a crucial role in oncology management. For 21% of patients the diagnosis was correctly altered by the MDM. The diagnostic accuracy of the MDM was 95%. The absence of a presenting doctor decreased this accuracy while duration of MDM and number of patients discussed did not affect this accuracy. The presence of research fellows prolonged the duration of the MDM.
Increased Plasma Levels of Von Willebrand Factor and Factor VIII (FVIII) During Acute Bacterial Infection Drive a Pro-Hemostatic Imbalance and Herald Severe Outcome in Cirrhosis
Authors: V. La Mura, A. Tripodi, G. Tosetti, V. Chantarangkul, L. Baronciani, F. Peyvandi, M. Iavarone, A. Sangiovanni, M. Primignani, M. Colombo
Journal: Journal of Hepatology (2016)
A Novel Innate Immunotherapy against HCC via Augmentation of NK Cell Cytotoxicity by Enhancing GWAS-Identified HCC Susceptibility Gene Expression
Authors: N. Kato, K. Goto, R. Muroyama, R. Nakagawa, Y. Matsubara, S. Morimoto, S. Ito, Y. Tanoue, M. Jinushi
Journal: Journal of Hepatology (2016)
The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood
Authors: Jurjen Versluis, Myriam Labopin, Gerard Socie, Wu Depei, Liisa Volin, Didier Blaise, Noel Milpied, Charles Craddock, Ibrahim Yakoub-Agha, Johan Maertens, Per T. Ljungman, Anne Huynh, Mauricette Michalet, Eric Deconinck, Patrice Chevallier, Nigel Russell, Jakob R Passweg, Gert J Ossenkoppele, Bob Lowenberg, Mohamad Mohty, Jan J Cornelissen, Arnon Nagler
Journal: Blood (2014)
Sarcopenia in patients with symptomatic polycystic liver disease: a more objective parameter for liver allocation?
Authors: Frederik Temmerman, Jacques Pirenne, Ragna Vanslembrouck, Walter Coudyzer, Diethard Monbaliu, Raymond Aerts, Wim Laleman, David Cassiman, Chris Verslype, Werner Van Steenbergen, Schalk Van der Merwe, Jos van Pelt, Joost Drenth, Frederik Nevens
Journal: Hepatology (2012)
African Americans with Hepatocellular Carcinoma in the U.S. have Higher Rates of Being Uninsured at Time of Diagnosis, are less Likely to have HCC with in Milan Criteria, and are less Likely to Receive Any Hepatocellular Carcinoma Treatment
Authors: J. Wang, J. Ha, M. Yan, M. Aguilar, R. Cheung, R. Wong
Journal: Journal of Hepatology (2016)
Five-Year Impact of a Continuous Quality Improvement Effort Implemented by a Network of Diabetes Outpatient Clinics
Journal: Diabetes Care (2007)

OBJECTIVE—To evaluate the impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics in Sicily, Italy. RESEARCH DESIGN AND METHODS—Twenty-two clinics adopted the same electronic medical record system. Process and intermediate outcomes indicators were identified and software was developed, enabling the extraction of the information needed for the profiling of quality of care. Data were centrally analyzed anonymously every year, and results were discussed in meetings with the participants. The performances of the different centers were ranked against the “best performers,” and the reasons for variation were discussed. RESULTS—From 2001 to 2005, a total of 26,782 patients aged ≥18 years have been seen in the participating clinics. Rates of monitoring of A1C, blood pressure, lipid profile, and microalbuminuria constantly increased over the years. The percentage of individuals with A1C values ≤7.0% increased by 16.6%, while the proportion of patients with blood pressure ≤130/85 mmHg increased by 10.7%. The percentage of individuals with LDL cholesterol levels &amp;lt;100 mg/dl had a marked increase from 19.4 to 44.1%. Rates of use of lipid-lowering drugs, antihypertensive drugs, and aspirin also substantially raised over the years. CONCLUSIONS—We found a strong consistency between increasing rates of monitoring, increasing drug prescription, and better levels of intermediate outcomes. Despite the satisfactory achievements, a substantial room for improvement in the care of diabetes still persists.
Relationship of pleural fluid analysis with outcomes in cancer patients.
Authors: Ioana Bonta, Sharon Wesley Dev Sahadevan, Christopher Parks, Patricia L. Thompson, Dacian Bonta, Rabih Bechara
Journal: Journal of Clinical Oncology (2016)

e23214 Background: Pleural effusion is common occurrence in cancer patients, with an estimated annual incidence of 150 000 in the United States. It generally represents advanced malignant disease, current guidelines quote median survivals of between 3 and 12 months, and it greatly impairs quality of life. Methods: We performed a retrospective analysis of a dataset of 62 cancer patients with pleural effusion after first thoracentesis procedure. The recorded data included: age , gender, type of cancer, pleural fluid volume and characteristics. We analyzed the correlation of pleural fluid LDH, volume and cellularity with survival using Pearson rank correlation. Results: Sixty-two patients were studied, with ages between 20-77 years, median 57 years; 64% were females and 36% males. The number of patients deceased by the end of follow up was 43 (69.4%), alive at the end of follow up was 8 (12.9%) and lost to follow up 11 (17.7%). The cancer type was divided into breast cancer 32.3%, non-small cell lung cancer 25.8% and 41.9% other cancers. In our analysis, 33 (53.2%) patients had malignant pleural effusion with a median of 3 months of survival. A total of 29 (46.8%) patients had non-malignant effusion with a similar median survival of 3 months. Median pleural fluid volume was 1000 ml, median cellularity 675 cells per sample, and median LDH level 575.5. LDH and effusion volume correlate negatively with survival (correlation coefficient -0.45 and -0.35 respectively); cellularity has a weak correlation with survival (correlation coefficient 0.18). Subset analysis of the two most common cancers in our dataset (breast and NSCLC) showed pleural effusion volume, cellularity, and LDH values similar to those for the entire dataset (no statistical significant differences on subset analysis.) Conclusions: We found an inverse correlation between the pleural fluid volumes and LDH level and survival time among cancer patients after 1st thoracentesis. This correlation is maintained in subset analysis of the two most common types of cancer in our sample, breast and NSCLC. There was no difference in survival between patients with malignant and non-malignant effusions. A prospective study to better characterize the prognostic value of first thoracentesis may be warranted.
Sofosbuvir plus Simeprevir in Treatment-Naive and Treatment-Experienced Egyptian Patients with Hepatitis C Virus Infection: A Real Life Experience
Authors: G. Esmat, H.G. Eldeen, M. El Kassas, M. El Raziky, T. Elbaz, R. Fouad, M. Hussein, W. El-Hossary, A. Cordie, M. Korany, A. Abdelfattah, W. Doss, A. Yosry
Journal: Journal of Hepatology (2016)
Characteristics of adult osteosarcoma patients: Results from an ongoing postmarketing drug safety surveillance study.
Authors: K. D. Midkiff, A. Gilsenan, Y. Wu, D. Masica, E. Andrews
Journal: Journal of Clinical Oncology (2010)

1608 Background: Adult osteosarcoma is very rare (approximately 2 to 3 per million cases per year in adults aged 40 years and older), and few population-based or large case series studies are reported in the literature. To monitor for a potential signal of a possible association between teriparatide treatment and adult osteosarcoma, a 15-year surveillance study was initiated in 2002. Objectives:To characterize the demographic profile plus environmental and treatment exposures in adult osteosarcoma patients from an ongoing surveillance study. Methods: Incident cases of adult osteosarcoma diagnosed on or after January 1, 2003, are identified through population-based state cancer registries and comprehensive cancer center registries in the United States. Currently, 15 U.S. registries are participating (11 states, 1 SEER, and 3 comprehensive cancer centers). Once cases are identified and consent is obtained, information about demographics, prior treatment with osteoporosis medications, and exposure to possible osteosarcoma risk factors is ascertained by telephone interview. Results: As of September 2009, 979 cases of osteosarcoma diagnosed between January 1, 2003, and December 31, 2007, were identified and 365 interviews were completed (231 patients, 134 proxies). Characteristics were similar for interviewed and non-interviewed cases. Among all cases identified, mean age was 63 years, 49% were female, and 80% were white. Osteosarcoma NOS (67%) and chondroblastic osteosarcoma (12%) were the most common morphologic types; leg bones (29%) were the most common anatomical tumor site, followed by the pelvis/sacrum (17%). Among those interviewed, reported prevalence of possible risk factors was 27% for prior history of cancer, 20% for history of radiation therapy, 20% for prior trauma or infection at site of cancer, and 6% for history of Paget's disease. Conclusions: Data from this ongoing surveillance study are adding to the collective knowledge about adult patients with osteosarcoma. Results through the first 7 years of the study expand on information from the literature and describe the distribution of possible risk factors among adult osteosarcoma patients from a population-based case series. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Lilly Lilly Lilly
Quantification of Liver Fat Content: Diagnostic Evaluation of Proton Magnetic Resonance Spectroscopy Compared with Histological Methods
Authors: P. Nasr, M.F. Forsgren, S. Ignatova, O.D. Leinhard, N. Dahlström, M. Ekstedt, P. Lundberg, S. Kechagias
Journal: Journal of Hepatology (2016)
Deletional HPFH Vs. Delta Beta Thalassemia: Closing in on a Possible Hb F Silencer Location
Authors: Molly Susan Hein, Kenneth C Swanson, Patrick A Lundquist, Joella A Yungerberg, Lea M Coon, Brian D Dawson, Dragan Jevremovic, Andre M Oliveira, James D Hoyer, Jennifer L Oliveira
Journal: Blood (2015)
MIR-146A-5P, A Proviral Factor Up-Regulated by Hepatitis C Virus Infection, Deregulates Metabolic Pathways Relevant for Liver Disease Progression in Hepatocytes
Authors: S. Pernot, S. Bandiera, H. El Saghire, S.C. Durand, T. Ye, C. Thumann, E. Crouchet, C. Schuster, I. Fofana, M.H. Heim, T.F. Baumert, M.B. Zeisel
Journal: Journal of Hepatology (2016)
The type IIFN signature determines the sustained anti-citrullinated protein antibodies levels during TNF alpha blockade in rheumatoid arthritis
Authors: Tineke Cantaert, C. A Wijbrandts, T. Van Der Pouw Kraan, C Mavragani, Theo Niewold, L De Rycke, M. K Crow, P. P Tak, D Baeten
Journal: Annals of the Rheumatic Diseases (2008)
A Metabo-Transcriptomics Paired Analysis for Identification of Molecular Mechanisms in Severe Alcoholic Hepatitis non Responsive to Gluco-Corticosteroids Therapy
Authors: J.S. Maras, S. Das, Md.S. Hussain, S.M. Shasthry, S.K. Sharma, C. Junot, R. Moreau, S.K. Sarin
Journal: Journal of Hepatology (2016)